Home

Publications:

1. Esmail V, Al-Shamaa K, Hussein H, 2012. Early virological response of the first line combination therapy (pegylated interferon alfa- 2a and ribavirin) in Iraqi chronic hepatitis C patients and their adverse effects. Global Journal of Medical Research, 12(11): 35-46.

2. Esmail V, Hamid D, Ratha R, 2016. Prevalence of flu-like syndrome among chronic hepatitis C infected patients treated with the first line combination therapy (pegylated interferon A-2a and ribavirin). International Journal of Development Research, 6(2): 6605-6608.

3. Esmail V, Hamid D, Ratha R, 2016. Pegylated interferon a-2a therapy and occurrence of sinus tachycardia in chronic hepatitis C infected patients. Donnish Journal of Medicine and Medical Sciences, 3(1): 001-005.

4. Al-Nimer M, Esmail V, Mohammad O, 2019. Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study. Electronic Journal of General Medicine, 16(3): em 142.

5. A Preliminary report about the detection of ventricular repolarisation in patients with non-alcoholic fatty liver disease. Journal of Taibah University Medical Sciences 2020; 15(4); 284-91.

6. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab Journal of Gastroenterology 2021; 22(2021); 1-5.

7.Effects of orlistat or telmisartan on the serum free fatty acids in non-alcoholic fatty liver disease patients: an open-labeled randomized controlled study. Turk J Gastroenterol. 2022;33(5):421-426

E-mail: vian.wastaesmail@univsul.edu.iq

vianwasta85@gmail.com

Mobile: +964(0)7701944091